The Charles T. Campbell Eye Microbiology Lab
UPMC | University of Pittsburgh Medical CenterUniversity of Pittsburgh Schools of the Health Sciences
HomeAbout UsLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchContact Us


2001 Ocular Microbiology and Immunology Group, Abstract 11

OMIG Main Page | 2001 Abstracts| < Previous | Next>

In Vitro Antibiotic Susceptibility Testing of Second Generation Fluoroquinolone Resistant Pseudomonas Aeruginosa
R.P. Kowalski, L.M. Karenchak, E.G. Romanowski, F.S. Mah, D.C. Ritterband and J.S. Gordon
The University of Pittsburgh, Pittsburgh, PA and the NY Eye and Ear Infirmary, New York, NY

Purpose: The published incidence of second generation flouroquinolone (FQ) resistant Pseudomonas aeruginosa from keratitis has mandated our laboratory to investigate the best antibiotics to treat these ocular infections.

Methods: We determined the MICs of twelve second generation FQ P.aeruginosa isolates using Etests to gatifloxacin, moxifloxacin, trovofloxacin, polymyxin, gentamicin, amikacin, tobramycin, ceftazidime, and ticarcillin. Susceptibility was determined by comparing the MICs to the serum standards.

Results: The susceptibilities of second generation FQ P.aeruginosa isolates to amikacin, ceftazidine, tobramycin, polymyxin and gentamicin were 92% (11/12), 75% (9/12) 67% (8/12, 42% (5/12 and 17% (2/12), respectively. The susceptibilities of second generation FQ P.aeruginosa isolates to gatifloxacin, moxifloxacin, trovofloxacin, and ticarcillin were 0% (0/12).

Conclusions: Although this is a laboratory study that must be confirmed with in vivo studies, our results indicate that second generation FQ P.aeruginosa ocular infections may best be treated with aminoglycoside antibiotics (amikacin and tobramycin) or ceftazidime.

OMIG Main Page | 2001 Abstracts| < Previous | Next>

Top of Page


Web Site Terms of Use | E-mail Terms of Use | Medical Advice Disclaimer
UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences | Contact UPMC